Catabasis Pharmaceuticals Aktie
WKN DE: A3C2EY / ISIN: US04635X1028
06.08.2025 16:27:01
|
Astria Therapeutics Licenses Japan Rights To Navenibart In $16 Mln Deal
(RTTNews) - Astria Therapeutics (ATXS), Wednesday announced has granted exclusive development and commercialization rights in Japan for its investigational therapy navenibart to Kaken Pharmaceutical.
Navenibart, a long-acting monoclonal antibody in Phase 3 trials, is designed for the preventative treatment of hereditary angioedema.
Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for another $16 million in milestone payments, along with tiered royalties of up to 30 percent and partial cost reimbursement for Phase 3 development.
Kaken will support the ongoing ALPHA-ORBIT Phase 3 trial in Japan, manage regulatory submissions, and help prepare for commercialization. Astria expects the funding from this agreement to support its operations into 2028.
ATXS is currently trading at $6.99, down $0.03 or 0.43 percent on the Nasdaq.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Catabasis Pharmaceuticals Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Catabasis Pharmaceuticals Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Catabasis Pharmaceuticals Inc Registered Shs | 7,66 | 1,59% |
|